Literature DB >> 8174845

Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans.

M Uehara1, H Kishikawa, S Isami, K Kisanuki, Y Ohkubo, N Miyamura, T Miyata, T Yano, M Shichiri.   

Abstract

The present study compared the effect on insulin sensitivity of ACE inhibitors with a sulphydryl group (captopril) or those without a sulphydryl group (delapril and enalapril) during the hyperinsulinaemic euglycaemic clamp test in both animal and clinical experiments. A possible contribution of bradykinin to the improvement of insulin sensitivity by ACE-inhibition was also studied. In healthy control and depancreatized dog experiments, administration of captopril either intravenously (3.0 mmol.kg-1) or orally (5.0 mmol.kg-1) increased insulin sensitivity indices and plasma bradykinin concentrations. In comparison, intravenous administration of an active metabolite of delapril (3.0 mmol.kg-1) and oral administration of either delapril or enalapril (5.0 mmol.kg-1) showed slight, but not significant increases in insulin sensitivity indices and plasma bradykinin concentrations. Infusion of a bradykinin antagonist (N-alpha-adamantane-acetyl-D-Arg-[Hyp3,Thi5,8,D-Phe7]-b bradykinin) (0.5 nmol.kg-1 x min-1) abolished the effect of captopril on insulin sensitivity. Furthermore, intravenous administration of bradykinin (0.1 nmol.kg-1 x min-1) increased insulin sensitivity indices. In clinical experiments, insulin sensitivity indices decreased in the following order: normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients. In these four groups, oral administration of captopril (2.0 mmol.kg-1) significantly increased insulin sensitivity indices, and a concomitant increase in plasma bradykinin concentrations was observed. By contrast, oral administration of enalapril or delapril showed slight, but not significant effects on insulin sensitivity indices and plasma bradykinin concentrations. From these studies, it is concluded that ACE inhibitors with a sulphydryl group have more potent action on the improvement in insulin sensitivity than those without a sulphydryl group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174845     DOI: 10.1007/bf00398058

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  30 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

2.  ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients.

Authors:  G Paolisso; A Gambardella; M Verza; A D'Amore; S Sgambato; M Varricchio
Journal:  J Hum Hypertens       Date:  1992-06       Impact factor: 3.012

3.  [Improved insulin action by ACE inhibition in type-2 diabetics].

Authors:  K Rett; N Lotz; M Wicklmayr; E Fink; K W Jauch; B Günther; G Dietze
Journal:  Dtsch Med Wochenschr       Date:  1988-02-19       Impact factor: 0.628

4.  Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.

Authors:  A V Chobanian; C C Haudenschild; C Nickerson; R Drago
Journal:  Hypertension       Date:  1990-03       Impact factor: 10.190

5.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

6.  Potentiation of bradykinin-induced decrease of blood pressure in dogs by SO 14,551, the disulfide metabolite of captopril.

Authors:  N O'Hara; H Ono; K Hashimoto
Journal:  Jpn J Pharmacol       Date:  1982-10

Review 7.  Modulation of the action of insulin in relation to the energy state in skeletal muscle tissue: possible involvement of kinins and prostaglandins.

Authors:  G J Dietze
Journal:  Mol Cell Endocrinol       Date:  1982-02       Impact factor: 4.102

8.  Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.

Authors:  M Laakso; S V Edelman; G Brechtel; A D Baron
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

9.  Sulfhydryl group in angiotensin converting enzyme inhibitors and superoxide radical formation.

Authors:  J L Mehta; F A Nicolini; D L Lawson
Journal:  J Cardiovasc Pharmacol       Date:  1990-11       Impact factor: 3.105

10.  Improvement of impaired postoperative insulin action by bradykinin.

Authors:  K W Jauch; B Günther; W Hartl; K Rett; M Wicklmayr; G Dietze
Journal:  Biol Chem Hoppe Seyler       Date:  1986-03
View more
  12 in total

1.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

Review 2.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

3.  Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway.

Authors:  S Isami; H Kishikawa; E Araki; M Uehara; K Kaneko; T Shirotani; M Todaka; S Ura; S Motoyoshi; K Matsumoto; N Miyamura; M Shichiri
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

4.  Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.

Authors:  V Arbin; N Claperon; M C Fournié-Zaluski; B P Roques; J Peyroux
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

5.  Antihypertensive drug therapy and hypoglycemia in elderly diabetic patients treated with insulin and/or sulfonylureas. Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA).

Authors:  A Corsonello; C Pedone; F Corica; A Malara; L Carosella; A Sgadari; V N Mauro; D Ceruso; M Pahor; P Carbonin
Journal:  Eur J Epidemiol       Date:  1999-11       Impact factor: 8.082

6.  Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.

Authors:  J E Toblli; G Cao; G DeRosa; P Forcada
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

7.  Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.

Authors:  Orly Vardeny; Hajime Uno; Eugene Braunwald; Jean Lucien Rouleau; Bernard Gersh; Aldo P Maggioni; Michael Domanski; Marc A Pfeffer; Scott D Solomon
Journal:  Am J Cardiol       Date:  2011-04-18       Impact factor: 2.778

8.  The B2 receptor of bradykinin is not essential for the post-exercise increase in glucose uptake by insulin-stimulated mouse skeletal muscle.

Authors:  G G Schweitzer; C M Castorena; T Hamada; K Funai; E B Arias; G D Cartee
Journal:  Physiol Res       Date:  2011-03-14       Impact factor: 1.881

9.  Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance.

Authors:  Anura P Jayasooriya; Michael L Mathai; Lesley L Walker; Denovan P Begg; Derek A Denton; David Cameron-Smith; Gary F Egan; Michael J McKinley; Paula D Rodger; Andrew J Sinclair; John D Wark; Harrison S Weisinger; Mark Jois; Richard S Weisinger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

10.  Molecular scanning of the insulin receptor substrate-1 (IRS-1) gene in Japanese patients with NIDDM: identification of five novel polymorphisms.

Authors:  S Ura; E Araki; H Kishikawa; T Shirotani; M Todaka; S Isami; S Shimoda; R Yoshimura; K Matsuda; S Motoyoshi; N Miyamura; C R Kahn; M Shichiri
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.